Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by equities researchers at Oppenheimer in a research note issued to investors on Thursday.

A number of other research analysts have also recently commented on TEVA. Citigroup cut Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and lowered their target price for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. BidaskClub downgraded Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 16th. Mizuho restated a “neutral” rating and issued a $16.00 price objective (down from $30.00) on shares of Teva Pharmaceutical Industries in a research report on Tuesday, August 22nd. Credit Suisse Group downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Finally, TheStreet downgraded Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Seven equities research analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $19.34.

Teva Pharmaceutical Industries (NYSE:TEVA) traded down $0.82 during midday trading on Thursday, reaching $15.70. The company’s stock had a trading volume of 30,494,500 shares, compared to its average volume of 15,888,267. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $38.31. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. The stock has a market cap of $16,784.32, a PE ratio of 3.82 and a beta of 0.55.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Security National Bank of Sioux City Iowa IA lifted its holdings in Teva Pharmaceutical Industries by 0.4% during the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after buying an additional 87 shares during the period. Bronfman E.L. Rothschild L.P. grew its position in Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the period. Sheaff Brock Investment Advisors LLC grew its position in Teva Pharmaceutical Industries by 3.6% during the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock worth $279,000 after purchasing an additional 294 shares during the period. Bank of Nova Scotia grew its position in Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares during the period. Finally, First National Trust Co. grew its position in Teva Pharmaceutical Industries by 6.7% during the 2nd quarter. First National Trust Co. now owns 8,878 shares of the company’s stock worth $295,000 after purchasing an additional 555 shares during the period. 52.05% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/14/oppenheimer-reiterates-hold-rating-for-teva-pharmaceutical-industries-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.